Refreshing results…
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
Download from doi.orgPhase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation
Download from doi.orgAuthor Correction: Complement as a target in COVID-19?
Download from www.nature.comComplement as a target in COVID-19?
Download from www.nature.com‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development
Download from www.nature.comClinical promise of next-generation complement therapeutics
Download from www.nature.comNew insights into the immune functions of complement
Download from www.nature.comMissing publications? Search for publications with a matching author name.